11. Myasthenia gravis Clinical trials / Disease details


Clinical trials : 332 Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-002740-26-GB
(EUCTR)
21/02/200601/12/2005A Phase II Double Blind, Cross-Over Study to Compare the Safety and Efficacy of 10, 20 and 40 mg Monarsen (EN101) administered to Patients with Myasthenia GravisA Phase II Double Blind, Cross-Over Study to Compare the Safety and Efficacy of 10, 20 and 40 mg Monarsen (EN101) administered to Patients with Myasthenia Gravis Myasthenia Gravis
MedDRA version: 8.1;Level: LLT;Classification code 10028417;Term: Myasthenia gravis
Product Name: MONARSEN
Product Code: EN101
Other descriptive name: MONARSEN
Other descriptive name: MONARSEN
Other descriptive name: MONARSEN
Ester Neuroscience LtdNULLNot Recruiting Female: yes
Male: yes
30 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom